LL-37 (Cathelicidin) vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | IGF-1 LR3 |
|---|---|---|
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |
What They Have in Common
Both LL-37 (Cathelicidin) and IGF-1 LR3 are commonly used for: